Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain.

Carlos Taxonera Fernando de Andrés-NogalesSantiago García-LópezAmelia Sánchez-GuerreroBelén MenchénCarmen PeralAna CábezSusana GómezAlejandra López-Ibáñez de AldecoaMiguel Ángel CasadoLuis Menchén

Published in: Expert review of pharmacoeconomics & outcomes research (2021)

From the Spanish NHS perspective, tofacitinib could be a dominant treatment (less costly and more effective) in comparison to vedolizumab, with relevant cost savings and similar QALY gains.

Keyphrases

ulcerative colitis
rheumatoid arthritis
patient safety
early onset
high intensity
patients with inflammatory bowel disease